



ESUR17

24th Meeting of the EAU Section of Urological Research

In collaboration with the EAU Section of Uro-pathology **esup**

12-14 October 2017, Paris, France

www.esur17.org

esur

EAU
European
Association
of Urology

Scientific Programme

Thursday, 12 October 2017

- 10.00 – 14.30** **Registration**
- 12.00 – 14.00** **ESU Course**
Clinical and histopathological basics in bladder cancer: unmet needs
Chair : Bernard Malavaud, Toulouse (FR)
Faculty : Eva Comperat, Paris (FR)
 Bas van Rhijn, Amsterdam (NL)
- 14.30 – 14.40** **Opening**
Yves Allory, Paris (FR) Meeting Chair
Kerstin Junker, Homburg (DE) ESUR Chair
Rodolfo Montironi, Ancona (IT) ESUP Chair
- 14.40 – 15.55** **Session 1**
Tumour complexity 1: Microenvironment
Chairs: Mariangela Mancini, Padova (IT)
 Kristin Tasken, Oslo (NO)
- 14.40 – 15.05** **The role of nerves in cancer progression**
Claire Magnon, Paris (FR)
- 15.05 – 15.30** **The role of tumour microenvironment for drug resistance**
Arne Östman, Stockholm (SE)
- 15.30 – 15.55** **Immune cells: Role in tumour equilibrium and escape**
Thorvald van Hall, Leiden (NL)
- 15.55 – 16.20** **Break**
- 16.20 – 18.05** **Session 2**
Tumour complexity 2: Immune system
Chairs: Kerstin Junker, Homburg (DE)
 Egbert Oosterwijk, Nijmegen (NL)
- 16.20 – 16.45** **Immune scoring system in modern pathology: A new grading system?**
Georges Netto, Birmingham (US)
- 16.45– 17.05** **Response prediction for checkpoint inhibitors: More than target testing**
Emanuela Romano, Paris (FR)
- 17.05 – 17.25** **Targeting immunogenic cell death to treat prostate cancer**
Stephen Tait, Glasgow (GB)

17.25 – 18.05	Short presentations 1
17.25 – 17.35	O-1 Prognostic potential of histopathology combined with HPV status and microRNAs in penile squamous cell carcinomas Sebastian Hölters, Homburg (DE)
17.35 – 17.45	O-2 Protein tyrosine phosphatase activity correlates with tumor infiltrating lymphocyte levels in renal cell carcinoma tissues Jeanette Oosterwijk-Wakka, Nijmegen (NL)
17.45 – 17.55	O-3 MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis Carmen Jeronimo, Porto (PT)
17.55 – 18.05	O-4 MiR-424 upregulation influences the tumor microenvironment and prostate cancer progression Giuseppina Carbone, Bellinzona (CH)

Friday, 13 October 2017

- 08.30 – 10.15** **Session 3**
Tumour complexity 3: Model systems
Chairs: Imran Ahmad, Glasgow (GB)
Gabri van der Pluijm, Leiden (NL)
- 08.30 – 08.50** **In-vitro model systems: Organotypic tumour slice culture**
Geertje van der Horst, Leiden (NL)
- 08.50 – 09.15** **PDX models for anti-tumor activity studies of therapeutic compounds and resistance mechanisms in kidney, bladder and prostate cancers**
Thierry Massfelder, Strasbourg (FR)
- 09.15 – 09.35** **Human disease culture models on organ-on-chip devices: Towards a clinical trial-on-a-chip**
Anja van de Stolpe, Eindhoven (NL)
- 09.35 – 10.15** **Short presentations 2**
- 09.35 – 09.45** **O-5 A novel preclinical model of induced stemness and therapy resistance in urological cancers**
Anastasia Hepburn, Newcastle (GB)
- 09.45 – 09.55** **O-6 Precision systems medicine in urological tumors - Molecular profiling and functional testing**
Päivi Östling, Solna (SE)
- 09.55 – 10.05** **O7 - C.o.b.l.a.n.c.e. : A Cohort to study bladder cancer. Update of patient inclusions in 2017**
Simone Benhamou, Paris (FR)
- 10.05 – 10.15** **O8 - Novel panel of urinary biomarkers for urothelial cancer**
Tsung Wen Chong, Singapore (SG)
- 10.15 – 10.45** **Break**
- 10.45 -12.10** **Session 4**
Tumour heterogeneity in bladder cancer
Chairs: Yves Allory, Paris (FR)
Antonio Lopez-Beltran, Lisbon (PT)
- 10.45 – 11.05** **Tumour heterogeneity of FGFR3 mutations in invasive bladder cancer: Implications for peri-operative anti-FGFR3 treatment**
Bas van Rhijn, Amsterdam (NL)
- 11.05 – 11.30** **Clonal evolution and potential therapeutic targets in urothelial carcinoma**
Lars Dyrskjøt, Aarhus (DK)
- 11.30 – 11.50** **Urothelial carcinoma variants and molecular subtypes**
Antonio Lopez-Beltran, Lisbon (PT)
- 11.50 - 12.10** **How bladder cancer heterogeneity matters for the urologist?**
Evangelos Xylinas, Paris (FR)
- 12.10 – 13.15** **Lunch**
- 13.15 – 14.45** **Poster session 1**
Poster numbers P-1 to P25

14.30 – 14.45	Break
14.45 – 15.15	Dominique Chopin Lecture and Award Of cancer stem cells and bone metastasis in prostate cancer George Thalmann, Berne (CH)
15.15 – 15.40	EVs and therapy Lorraine O’Driscoll, Dublin (IE)
15.40 – 17.40	Session 5 DNA repair mechanisms Chairs: Felix Feng, San Francisco (US) Rodolfo Montironi, Ancona (IT)
15.40 – 16.05	DNA repair mechanisms: Role in disease development and treatment Dik van Gent, Rotterdam (NL)
16.05 – 16.30	Defects in DNA repair genes: Role in chemotherapy response in urological cancers David Liu, Cambridge (US)
16.30 – 16.55	The molecular rationale for PARP1 inhibitor function Felix Feng, San Francisco (US)
16.55 – 17.20	DNA repair in prostate cancer: Biology and clinical implications Joaquin Mateo, London (GB)
17.20 – 17.40	Short presentations 3
17.20 – 17.30	O-9 LINC00857 expression mediates platinum-based chemotherapy resistance in muscle-invasive bladder cancer cells Gerald Verhaegh, Nijmegen (NL)
17.30 – 17.40	O-10 Tissue proteomics of bladder cancer for drug target identification Marika Mokou, Athens (GR)

Saturday, 14 October 2017

- 08.45 – 10.25** **Session 6**
CRISPR
Carmen Jeronimo, Porto (PT)
Margaret Knowles, York (GB)
- 08.45 – 09.10** **CRISPR: New technical perspectives in research and treatment**
Rogier Louwen, Rotterdam (NL)
- 09.10 – 09.35** **CRISPR and transposon-based approaches for high-throughput functional cancer genomics in mice**
Roland Rad, Munich (DE)
- 09.35 – 10.25** **Short presentations 4**
- 09.35 – 09.45** **O-11 Identification of genomic features underlying response of muscle-invasive bladder cancer (MIBC) to neoadjuvat sorafenib, gemcitabine, and cisplatin (SGC) in an open-label, single-arm, phase 2 study**
D. Raggi, Milan (IT)
- 09.45 – 09.55** **O-12 Small molecule EMT-inhibitors are capable of reducing human prostate cancer aggressiveness and metastasis**
Marjan Van de Merbel, Leiden (NL)
- 09.55 – 10.05** **O-13 Circulating tumor cells as liquid biopsies of skeletal metastases from prostate cancer**
Karin Welen, Gothenburg (SE)
- 10.05 – 10.15** **O-14 Circulating microRNAs as prognostic biomarkers in upper tract urothelial carcinoma**
Ruth Montalbo, Barcelona (ES)
- 10.15 – 10.25** **O-15 Systematic evaluation of techniques for the isolation and detection of small non-coding RNA from urine-derived extracellular vesicles**
Elena Martens-Uzunova, Rotterdam (NL)
- 10.25 – 11.00** **Break**
- 11.00 – 12.30** **Session 7**
ARTP: Prostate cancer
Chairs: Jocelyn Ceraline, Strasbourg (FR)
Palma Rocchi, Marseille (FR)
- 11.00 – 11.20** **Targeting Hsp27 signaling pathways in castrate-resistant prostate cancer**
Palma Rocchi, Marseille (FR)
- 11.20 – 11.40** **Sphingosine 1-Phosphate metabolism in prostate cancer bone metastasis**
Olivier Cuvillier, Toulouse (FR)
- 11.40 – 12.30** **Short presentations 5**
- 11.40 – 11.50** **O-16 Analysis of signal transduction pathway activity in prostate cancer for improved prognosis and targeted therapy response prediction**
Anja Van de Stolpe, Eindhoven (NL)

11.50 - 12.00	O-17 Poor differentiation is associated with low ADRB2 and induction of canonical WNT activity in prostate cancer cells Peder Braadland, Oslo (NO)
12.00 - 12.10	O-18 Identification of bipotent basal stem cells and unipotent luminal stem cells in adult human prostate epithelium Mohammad Moad, Newcastle (GB)
12.10 - 12.20	O-19 Dynamics of dissemination, dormancy and metastasis of prostate cancer: unravelling the metastatic process Jeroen Van Dorp, Rotterdam (NL)
12.20 - 12.30	O-20 MCAM supports the bone metastatic phenotype in human prostate cancer Eugenio Zoni, Berne (CH)
12.30 - 13.30	Lunch
13.30 - 15.00	Poster session 2 Poster numbers P-26 - P-52
14.15 - 15.00	Break
15.00 - 15.30	ESOU Lecture To be announced
15.30 - 16.15	Session 8 Liquid biopsies: Extracellular vesicles Chairs: Guido Jenster, Rotterdam (NL) Antonia Vlahou, Athens (GR)
15.30 - 15.55	Standardized analysis of extracellular vesicles in liquid biopsies An Hendrix, Ghent (BE)
15.55 - 16.15	Short presentations 6
15.55 - 16.05	O-21 EVQuant: Combined quantification and characterization of individual extracellular vesicles in experimental and clinical samples Martin Van Royen, Rotterdam (NL)
16.05 - 16.15	O-22 Extracellular vesicles released from mesenchymal prostate cancer cells induce epithelial to mesenchymal transition in recipient epithelial carcinoma cells Nanor Sirab, Creteil (FR)
16.15 - 16.30	ARTP Award and closing remarks